Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patientsM de Forni, G G Chabot, J P Armand, et al.
Nephron|January 1, 1994
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiencyE Chatelut, L Rostaing, V Gualano, et al.
Clinical Pharmacology and Therapeutics|March 1, 1992
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicitiesP Canal, J Robert, M Ramon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC)J Chauvergne, P Fumoleau, P Cappelaere, et al.
Cancer Research|August 15, 1994
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patientsM de Forni, R Bugat, G G Chabot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsG G Chabot, D Abigerges, G Catimel, et al.
British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical studyM de Forni, M C Malet-Martino, P Jaillais, et al.
The Journal of Laryngology and Otology|October 1, 1993
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomasJ M Bachaud, J M David, R E Shubinski, et al.
Pageof 4